Yazar "Sezer, A." seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3(Elsevier, 2023) Makharadze, T.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1(ELSEVIER SCIENCE INC, 2021) Bondarenko, I.; Sezer, A.; Kılıçkap, Saadettin; Gümüş, M.; Özgüroğlu, M.; Gogishvili, M.; urk, H. M.; Cicin, I.[No Abstract Available]Öğe Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.[Abstract Not Available]Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3(Elsevier Science Inc, 2023) Kalinka, E.; Bondarenko, I.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Makharadze, T.[Abstract Not Available]Öğe Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroups(ELSEVIER, 2022) Sezer, A.; Kılıçkap, Saadettin; Gümüş, M; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; He, X.; Gullo, Guiseppe; Rietschel, Petra; Quek, RubenPatient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroupsÖğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]
